NCT02250937View on ClinicalTrials.gov

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 27, 2014

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSCT

DRUG

Busulfan

Given IV

DRUG

Cladribine

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

OTHER

Pharmacological Study

Correlative studies

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER